Technical Analysis for RIGL - Rigel Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
RIGL closed down 0.48 percent on Friday, January 18, 2019, on 3.18 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical RIGL trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||New Downtrend||Bearish||0.00%|
|Jan 18||Volume Surge||Other||0.00%|
|Jan 18||Stochastic Reached Oversold||Weakness||0.00%|
|Jan 18||Outside Day||Range Expansion||0.00%|
|Jan 18||Down 3 Days in a Row||Weakness||0.00%|
|Jan 18||Oversold Stochastic||Weakness||0.00%|
|Jan 17||NR7||Range Contraction||-0.48%|
|Jan 16||MACD Bearish Signal Line Cross||Bearish||-2.34%|
|Jan 16||180 Bearish Setup||Bearish Swing Setup||-2.34%|
|Jan 14||Wide Bands||Range Expansion||-1.88%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more RIGL news...
|52 Week High||4.71|
|52 Week Low||1.96|
|200-Day Moving Average||3.0705|
|50-Day Moving Average||2.5644|
|20-Day Moving Average||2.243|
|10-Day Moving Average||2.243|
|Average True Range||0.157|
|Chandelier Exit (Long, 3 ATRs )||2.299|
|Chandelier Exit (Short, 3 ATRs )||2.431|
|Upper Bollinger Band||2.481|
|Lower Bollinger Band||2.005|
|Percent B (%b)||0.18|
|MACD Signal Line||-0.1204|
|Market Cap||259.98 Million|
|Num Shares||124 Million|
|Price-to-Earnings (P/E) Ratio||-3.07|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||2.30|
|Resistance 3 (R3)||2.31||2.25||2.27|
|Resistance 2 (R2)||2.25||2.20||2.25||2.25|
|Resistance 1 (R1)||2.17||2.16||2.14||2.16||2.24|
|Support 1 (S1)||2.03||2.06||2.00||2.02||1.94|
|Support 2 (S2)||1.97||2.02||1.97||1.93|
|Support 3 (S3)||1.89||1.97||1.92|
|Support 4 (S4)||1.88|